利用纵向诊断和用药记录的深度序列模型预测胰腺癌风险。

IF 10.6 1区 医学 Q1 CELL BIOLOGY
Chunlei Zheng, Asif Khan, Daniel Ritter, Debora S Marks, Nhan V Do, Nathanael R Fillmore, Chris Sander
{"title":"利用纵向诊断和用药记录的深度序列模型预测胰腺癌风险。","authors":"Chunlei Zheng, Asif Khan, Daniel Ritter, Debora S Marks, Nhan V Do, Nathanael R Fillmore, Chris Sander","doi":"10.1016/j.xcrm.2025.102359","DOIUrl":null,"url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is a rare, aggressive cancer often diagnosed late with low survival rates, due to the lack of population-wide screening programs and the high cost of early detection methods. To enable early detection of high-risk individuals, we develop a transformer-based model trained on longitudinal Veterans Affairs electronic health record (EHR) with 19,426 PDAC cases and ∼15.9 million controls. Our model combines diagnostic and medication trajectories to predict PDAC risk within a 6-, 12-, and 36-month assessment window. Incorporating medication significantly improved performance; among the top 1,000-5,000 highest-risk patients in a cohort of 1 million patients, 3-year PDAC incidence is 115-70 times higher than a reference estimate based on age and sex alone. Furthermore, analysis of most predictive features highlights the role of events such as chronic inflammatory conditions and specific medications on overall PDAC risk. Our work provides an AI-driven identification of high-risk individuals, with a potential to improve early detection, enhance patient care, and reduce healthcare costs.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"6 9","pages":"102359"},"PeriodicalIF":10.6000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490214/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pancreatic cancer risk prediction using deep sequential modeling of longitudinal diagnostic and medication records.\",\"authors\":\"Chunlei Zheng, Asif Khan, Daniel Ritter, Debora S Marks, Nhan V Do, Nathanael R Fillmore, Chris Sander\",\"doi\":\"10.1016/j.xcrm.2025.102359\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is a rare, aggressive cancer often diagnosed late with low survival rates, due to the lack of population-wide screening programs and the high cost of early detection methods. To enable early detection of high-risk individuals, we develop a transformer-based model trained on longitudinal Veterans Affairs electronic health record (EHR) with 19,426 PDAC cases and ∼15.9 million controls. Our model combines diagnostic and medication trajectories to predict PDAC risk within a 6-, 12-, and 36-month assessment window. Incorporating medication significantly improved performance; among the top 1,000-5,000 highest-risk patients in a cohort of 1 million patients, 3-year PDAC incidence is 115-70 times higher than a reference estimate based on age and sex alone. Furthermore, analysis of most predictive features highlights the role of events such as chronic inflammatory conditions and specific medications on overall PDAC risk. Our work provides an AI-driven identification of high-risk individuals, with a potential to improve early detection, enhance patient care, and reduce healthcare costs.</p>\",\"PeriodicalId\":9822,\"journal\":{\"name\":\"Cell Reports Medicine\",\"volume\":\"6 9\",\"pages\":\"102359\"},\"PeriodicalIF\":10.6000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490214/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell Reports Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.xcrm.2025.102359\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Reports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.xcrm.2025.102359","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

胰腺导管腺癌(PDAC)是一种罕见的侵袭性癌症,由于缺乏全民筛查计划和早期检测方法的高成本,通常诊断较晚,生存率低。为了能够早期发现高风险个体,我们开发了一个基于变压器的模型,该模型接受了纵向退伍军人事务电子健康记录(EHR)的培训,其中包括19,426例PDAC病例和约1590万对照。我们的模型结合了诊断和用药轨迹,在6个月、12个月和36个月的评估窗口内预测PDAC的风险。结合药物治疗可显著改善表现;在100万患者队列中的前1000 - 5000名高危患者中,3年PDAC发病率比仅基于年龄和性别的参考估计高115-70倍。此外,对大多数预测特征的分析强调了慢性炎症条件和特定药物等事件对PDAC总体风险的作用。我们的工作提供了一种人工智能驱动的高风险个体识别,有可能改善早期发现,加强患者护理,并降低医疗成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pancreatic cancer risk prediction using deep sequential modeling of longitudinal diagnostic and medication records.

Pancreatic ductal adenocarcinoma (PDAC) is a rare, aggressive cancer often diagnosed late with low survival rates, due to the lack of population-wide screening programs and the high cost of early detection methods. To enable early detection of high-risk individuals, we develop a transformer-based model trained on longitudinal Veterans Affairs electronic health record (EHR) with 19,426 PDAC cases and ∼15.9 million controls. Our model combines diagnostic and medication trajectories to predict PDAC risk within a 6-, 12-, and 36-month assessment window. Incorporating medication significantly improved performance; among the top 1,000-5,000 highest-risk patients in a cohort of 1 million patients, 3-year PDAC incidence is 115-70 times higher than a reference estimate based on age and sex alone. Furthermore, analysis of most predictive features highlights the role of events such as chronic inflammatory conditions and specific medications on overall PDAC risk. Our work provides an AI-driven identification of high-risk individuals, with a potential to improve early detection, enhance patient care, and reduce healthcare costs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cell Reports Medicine
Cell Reports Medicine Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
15.00
自引率
1.40%
发文量
231
审稿时长
40 days
期刊介绍: Cell Reports Medicine is an esteemed open-access journal by Cell Press that publishes groundbreaking research in translational and clinical biomedical sciences, influencing human health and medicine. Our journal ensures wide visibility and accessibility, reaching scientists and clinicians across various medical disciplines. We publish original research that spans from intriguing human biology concepts to all aspects of clinical work. We encourage submissions that introduce innovative ideas, forging new paths in clinical research and practice. We also welcome studies that provide vital information, enhancing our understanding of current standards of care in diagnosis, treatment, and prognosis. This encompasses translational studies, clinical trials (including long-term follow-ups), genomics, biomarker discovery, and technological advancements that contribute to diagnostics, treatment, and healthcare. Additionally, studies based on vertebrate model organisms are within the scope of the journal, as long as they directly relate to human health and disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信